MedTrace Logo

Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod

NCT01790269 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2021-07-29

No results posted yet for this study

Summary

Data on fingolimod effects on NK cells are so far conflicting. A longitudinal study on fingolimod treated kidney transplant patients showed that NK cells were not influenced in any of the treatment groups. However, more recent reports indicate an increased frequency of NK cells in peripheral blood and CSF of MS patients treated with fingolimod and a relative reduction of immature CD56bright NK cells in fingolimod-treated MS patients. It has been demonstrated that the expression of NK cell relevant sphingosine 1-phosphate (S1P) receptors seems to increase during NK cell maturation. Thus, different NK cell sub-types may response differently to S1P-receptor agonist such as fingolimod.

Therefore, the investigators aim to investigate longitudinally (baseline vs. treatment) the effects of fingolimod on NK cell maturation/differentiation.

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Sponsors & Collaborators

  • Dr. Carmen Infante-Duarte

    collaborator UNKNOWN

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Jan-Markus Dörr, MD · Charite Universitätsmedizin Berlin

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01790269 on ClinicalTrials.gov